Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026. The company will host a Fireside Chat on April 14, 2026 at 11:00 AM ET.
According to the company, the live webcast is available in the Events section of its website, and a replay will be accessible for 180 days after the conference.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ARQT
On the day this news was published, ARQT gained 2.29%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.5% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $66M to the company's valuation, bringing the market cap to $2.94B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows biotech peers like AGIO and OCUL up about 14–15%, but ARQT’s direction flag is null and sector move is marked false, suggesting stock-specific positioning rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Clinical data presentations | Positive | -2.1% | New clinical and long-term ZORYVE data at dermatology conference. |
| Mar 10 | Clinical data publication | Positive | -0.9% | Positive long-term safety and efficacy data for ZORYVE cream in children. |
| Mar 05 | Management promotion | Positive | -0.6% | Promotion of Chief Legal Officer to support commercialization and pipeline. |
| Mar 03 | Early-stage trial start | Positive | -4.7% | Initiation of Phase 1a/1b study of ARQ-234 in atopic dermatitis. |
| Feb 27 | Conference appearance | Positive | -8.2% | Management participation and fireside chat at TD Cowen conference. |
Recent ARQT news has generally been positive (clinical data, management, conferences) yet 24h price reactions have been negative after each event, indicating a pattern of selling or muted response on good news.
Over the last month, Arcutis reported multiple positive updates: new clinical and long‑term data for the ZORYVE portfolio (Mar 10, Mar 18), early‑stage development progress with ARQ-234 (Mar 3), and a management promotion to support its next growth phase (Mar 5). It also announced another conference appearance at TD Cowen on Feb 27. Despite constructive fundamentals, each of these headlines saw negative 24‑hour price reactions, framing today’s Needham conference news within a backdrop of consistent post‑news weakness.
Regulatory & Risk Context
An effective S-3ASR shelf filed on 2026-02-25 registers multiple securities (common and preferred stock, debt, warrants, purchase contracts and units) and allows selling securityholders to resell shares, with the company stating it will not receive proceeds from those resales.
Market Pulse Summary
This announcement details Arcutis management’s participation in the 25th Annual Needham Virtual Healthcare Conference, including a fireside chat on April 14, 2026 and a webcast replay for 180 days. It continues a pattern of active conference engagement following recent clinical data and pipeline updates. Historically, similar news has not produced sustained upside, so investors may focus more on future clinical milestones, commercialization progress for ZORYVE, insider activity, and any use of the effective shelf registration when assessing the story.
AI-generated analysis. Not financial advice.
WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Details for the Company’s participation are as follows:
Fireside Chat: Tuesday, April 14, 2026 at 11:00 am ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
